Immunotherapy combo shows promise against aggressive kidney cancer
NCT ID NCT05148546
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests three different immunotherapy combinations given before surgery to patients with high-risk clear cell kidney cancer. The goal is to see if these drugs can shrink the tumor and reduce the risk of the cancer returning. About 69 participants will receive either nivolumab alone, nivolumab plus ipilimumab, or nivolumab plus relatlimab, followed by surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab, ipilimumab, and relatlimab (immunotherapy drugs)
What this could lead to
If successful, this could lead to a new treatment approach that lowers the chance of kidney cancer coming back after surgery.
What could go wrong
This is an early phase II trial with only 69 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Netherlands Cancer Institute
Amsterdam, North Holland, 1066CX, Netherlands
-
Royal Free London NHS Foundation Trust
London, NW3 2QG, United Kingdom